In addition, osimertinib can effectively cross the blood–brain barrier and is effective in patients with brain metastases (including meningeal metastases) from lung cancer, which is a major advantage over other small-molecule EGFR inhibitors [114,115,116]. Here, EGFR is linked to lung cancer.